Nektar Therapeutics (NASDAQ:NKTR) shares saw an uptick in trading volume on Friday . 2,336,979 shares traded hands during trading, an increase of 99% from the previous session’s volume of 1,175,424 shares.The stock last traded at $17.30 and had previously closed at $16.10.

Several brokerages have commented on NKTR. Zacks Investment Research downgraded shares of Nektar Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, May 2nd. Brean Capital reiterated a “buy” rating on shares of Nektar Therapeutics in a report on Wednesday, May 4th. Finally, Piper Jaffray Cos. reiterated a “buy” rating and issued a $17.00 price objective on shares of Nektar Therapeutics in a report on Wednesday, May 4th. One analyst has rated the stock with a sell rating, five have assigned a buy rating and one has given a strong buy rating to the company. Nektar Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $18.20.

The stock’s market capitalization is $2.36 billion. The firm’s 50-day moving average is $15.03 and its 200-day moving average is $14.02.

Nektar Therapeutics (NASDAQ:NKTR) last announced its earnings results on Tuesday, May 3rd. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.09. During the same quarter in the previous year, the company earned $0.25 earnings per share. The company earned $58.88 million during the quarter, compared to the consensus estimate of $43.78 million. The business’s revenue was down 45.9% on a year-over-year basis. Equities analysts anticipate that Nektar Therapeutics will post ($0.95) EPS for the current fiscal year.

In related news, CEO Howard W. Robin sold 2,170 shares of the company’s stock in a transaction that occurred on Tuesday, May 17th. The stock was sold at an average price of $13.58, for a total value of $29,468.60. Following the sale, the chief executive officer now directly owns 19,103 shares in the company, valued at $259,418.74. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Robert Chess sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, July 1st. The shares were sold at an average price of $14.10, for a total value of $70,500.00. The disclosure for this sale can be found here.

A number of hedge funds recently made changes to their positions in the stock. Nationwide Fund Advisors boosted its stake in shares of Nektar Therapeutics by 2.1% in the fourth quarter. Nationwide Fund Advisors now owns 86,558 shares of the biopharmaceutical company’s stock valued at $1,459,000 after buying an additional 1,781 shares during the last quarter. Rhumbline Advisers boosted its stake in shares of Nektar Therapeutics by 6.5% in the fourth quarter. Rhumbline Advisers now owns 179,459 shares of the biopharmaceutical company’s stock valued at $3,024,000 after buying an additional 10,900 shares during the last quarter. Comerica Bank boosted its stake in shares of Nektar Therapeutics by 0.6% in the fourth quarter. Comerica Bank now owns 135,326 shares of the biopharmaceutical company’s stock valued at $1,992,000 after buying an additional 828 shares during the last quarter. New York State Common Retirement Fund boosted its stake in shares of Nektar Therapeutics by 1.9% in the fourth quarter. New York State Common Retirement Fund now owns 177,127 shares of the biopharmaceutical company’s stock valued at $2,985,000 after buying an additional 3,300 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its stake in shares of Nektar Therapeutics by 4.9% in the fourth quarter. Principal Financial Group Inc. now owns 1,208,204 shares of the biopharmaceutical company’s stock valued at $20,359,000 after buying an additional 56,510 shares during the last quarter.

Nektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.